title: FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.
abstract: We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR=24, TE=5, flip angle 40 degrees, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. Monte.buchsbaum@gmail.com
authors.forename: Monte S
authors.initials: MS
authors.lastname: Buchsbaum
authors.forename: M Mehmet
authors.initials: MM
authors.lastname: Haznedar
authors.forename: Jonathan
authors.initials: J
authors.lastname: Aronowitz
authors.forename: Adam M
authors.initials: AM
authors.lastname: Brickman
authors.forename: Randall E
authors.initials: RE
authors.lastname: Newmark
authors.forename: Rachel
authors.initials: R
authors.lastname: Bloom
authors.forename: Jesse
authors.initials: J
authors.lastname: Brand
authors.forename: Kim E
authors.initials: KE
authors.lastname: Goldstein
authors.forename: Desmond
authors.initials: D
authors.lastname: Heath
authors.forename: Meghan
authors.initials: M
authors.lastname: Starson
authors.forename: Erin A
authors.initials: EA
authors.lastname: Hazlett
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism*; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009483:Neuropsychological Tests; D009778:Occipital Lobe / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D000077152:Olanzapine; D049268:Positron-Emission Tomography; D011618:Psychotic Disorders / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013702:Temporal Lobe / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine